Drug Trial Radar · NCT05000450
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Jun 6, 2021
Primary completion
Oct 11, 2023
Study completion Oct 11, 2023
Sponsor
- Lead sponsor
- Allogene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
ALLO-605Genetic
ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
ALLO-647Biological
ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
FludarabineDrug
Chemotherapy for lymphodepletion
CyclophosphamideDrug
Chemotherapy for lymphodepletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-605 that will determine MTD/MAD and select the recommended Phase 2 dose (RP2D) of ALLO-605.Time frame: 28 days
- Phase 1: Proportion of patients experiencing Dose Limiting Toxicities with ALLO-647 [administered in combination with fludarabine/cyclophosphamide administered prior to ALLO-605]Time frame: 30 days
- Phase 2: To assess clinical efficacy of ALLO-605 as measured by overall response rate (ORR)Time frame: 12 months of study follow-up
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Sarah Cannon/Colorado Blood Cancer Institute
Denver, Colorado
St. David's South Austin Medical Center
Austin, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Transplant Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.